{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:10:14Z","timestamp":1794093014291,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["6020-20"],"award-info":[{"award-number":["6020-20"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA 240139"],"award-info":[{"award-number":["P30 CA 240139"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-023-00657-1","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T17:02:57Z","timestamp":1699549377000},"page":"1660-1674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1620","authenticated-orcid":false,"given":"Francesco","family":"Maura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":false,"given":"Kylee","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Gagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8638-9365","authenticated-orcid":false,"given":"Benjamin","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Ghamlouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9319-8866","authenticated-orcid":false,"given":"Patrick","family":"Blaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bachisio","family":"Ziccheddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Cirrincione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7176-6108","authenticated-orcid":false,"given":"Monika","family":"Chojnacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-0917","authenticated-orcid":false,"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-9561","authenticated-orcid":false,"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":false,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2594","authenticated-orcid":false,"given":"Carlyn","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":false,"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaldo","family":"Arbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Roshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Korde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-6360","authenticated-orcid":false,"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"657_CR1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar, S. V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol. 95, 548\u2013567 (2020).","journal-title":"Am. J. Hematol."},{"key":"657_CR2","doi-asserted-by":"crossref","first-page":"m3176","DOI":"10.1136\/bmj.m3176","volume":"370","author":"UA Shah","year":"2020","unstructured":"Shah, U. A. & Mailankody, S. Emerging immunotherapies in multiple myeloma. BMJ 370, m3176 (2020).","journal-title":"BMJ"},{"key":"657_CR3","doi-asserted-by":"crossref","unstructured":"Costa, L. J. et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J. Clin. Oncol. 40, 2901\u20132912 (2022).","DOI":"10.1200\/JCO.21.01935"},{"key":"657_CR4","doi-asserted-by":"crossref","unstructured":"Derman, B. A. et al. Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease-adapted study. JAMA Oncol. 8,1278\u20131286 (2022).","DOI":"10.1001\/jamaoncol.2022.2424"},{"key":"657_CR5","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","volume":"8","author":"B Diamond","year":"2021","unstructured":"Diamond, B. et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 8, e422\u2013e432 (2021).","journal-title":"Lancet Haematol."},{"key":"657_CR6","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"657_CR7","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl. J. Med. 380, 2104\u20132115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"657_CR8","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","volume":"7","author":"O Landgren","year":"2021","unstructured":"Landgren, O. et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol. 7, 862\u2013868 (2021).","journal-title":"JAMA Oncol."},{"key":"657_CR9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394, 29\u201338 (2019).","journal-title":"Lancet"},{"key":"657_CR10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","volume":"139","author":"J San-Miguel","year":"2022","unstructured":"San-Miguel, J. et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood 139, 492\u2013501 (2022).","journal-title":"Blood"},{"key":"657_CR11","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees, P. M. et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136, 936\u2013945 (2020).","journal-title":"Blood"},{"key":"657_CR12","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","volume":"128","author":"KM Kortum","year":"2016","unstructured":"Kortum, K. M. et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood 128, 1226\u20131233 (2016).","journal-title":"Blood"},{"key":"657_CR13","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","volume":"36","author":"K Misund","year":"2022","unstructured":"Misund, K. et al. Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia 36, 1887\u20131897 (2022).","journal-title":"Leukemia"},{"key":"657_CR14","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32145-y","volume":"13","author":"L Rasche","year":"2022","unstructured":"Rasche, L. et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat. Commun. 13, 4517 (2022).","journal-title":"Nat. Commun."},{"key":"657_CR15","doi-asserted-by":"crossref","first-page":"101145","DOI":"10.1016\/j.beha.2020.101145","volume":"33","author":"F Maura","year":"2020","unstructured":"Maura, F., Rustad, E. H., Boyle, E. M. & Morgan, G. J. Reconstructing the evolutionary history of multiple myeloma. Best Pract. Res. Clin. Haematol. 33, 101145 (2020).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"657_CR16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","volume":"1","author":"EH Rustad","year":"2020","unstructured":"Rustad, E. H. et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 1, 258\u2013273 (2020).","journal-title":"Blood Cancer Discov."},{"key":"657_CR17","doi-asserted-by":"crossref","first-page":"e127807","DOI":"10.1172\/jci.insight.127807","volume":"5","author":"JK Bailur","year":"2019","unstructured":"Bailur, J. K. et al. Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight 5, e127807 (2019).","journal-title":"JCI Insight"},{"key":"657_CR18","doi-asserted-by":"crossref","unstructured":"Dhodapkar, K. M. et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 3, 490\u2013501 (2022).","DOI":"10.1158\/2643-3230.BCD-22-0018"},{"key":"657_CR19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij, O. et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer 1, 493\u2013506 (2020).","journal-title":"Nat Cancer"},{"key":"657_CR20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/ni.2796","volume":"15","author":"PK Chattopadhyay","year":"2014","unstructured":"Chattopadhyay, P. K., Gierahn, T. M., Roederer, M. & Love, J. C. Single-cell technologies for monitoring immune systems. Nat. Immunol. 15, 128\u2013135 (2014).","journal-title":"Nat. Immunol."},{"key":"657_CR21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson, P. G. et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N. Engl. J. Med. 387, 132\u2013147 (2022).","journal-title":"N. Engl. J. Med."},{"key":"657_CR22","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura, F. et al. A practical guide for mutational signature analysis in hematological malignancies. Nat. Commun. 10, 2969 (2019).","journal-title":"Nat. Commun."},{"key":"657_CR23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15740-9","volume":"11","author":"EH Rustad","year":"2020","unstructured":"Rustad, E. H. et al. Timing the initiation of multiple myeloma. Nat. Commun. 11, 1917 (2020).","journal-title":"Nat. Commun."},{"key":"657_CR24","doi-asserted-by":"crossref","unstructured":"Maura, F. et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia 32,1044\u20131048 (2018).","DOI":"10.1038\/leu.2017.345"},{"key":"657_CR25","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997 (2015).","journal-title":"Nat. Commun."},{"key":"657_CR26","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura, F. et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat. Commun. 10, 3835 (2019).","journal-title":"Nat. Commun."},{"key":"657_CR27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker, B. A. et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132, 587\u2013597 (2018).","journal-title":"Blood"},{"key":"657_CR28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen, Y. C. et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat. Med. 27, 491\u2013503 (2021).","journal-title":"Nat. Med."},{"key":"657_CR29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn, C. et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 24, 289\u2013304 (2013).","journal-title":"Cancer Cell"},{"key":"657_CR30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"657_CR31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","volume":"137","author":"S Gooding","year":"2021","unstructured":"Gooding, S. et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood 137, 232\u2013237 (2021).","journal-title":"Blood"},{"key":"657_CR32","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-20-4366","volume":"27","author":"B Ziccheddu","year":"2021","unstructured":"Ziccheddu, B. et al. Functional impact of genomic complexity on the transcriptome of multiple myeloma. Clin. Cancer Res. 27, 6479\u20136490 (2021).","journal-title":"Clin. Cancer Res."},{"key":"657_CR33","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621\u20132633 (2021).","journal-title":"Blood"},{"key":"657_CR34","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf, T. et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 1, 2105\u20132114 (2017).","journal-title":"Blood Adv."},{"key":"657_CR35","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","volume":"26","author":"G Monaco","year":"2019","unstructured":"Monaco, G. et al. RNA-seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types. Cell Rep. 26, 1627\u20131640.e1627 (2019).","journal-title":"Cell Rep."},{"key":"657_CR36","doi-asserted-by":"crossref","unstructured":"Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 41, 711\u2013725.e6 (2023).","DOI":"10.1016\/j.ccell.2023.02.008"},{"key":"657_CR37","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/sim.7263","volume":"36","author":"AK Dwivedi","year":"2017","unstructured":"Dwivedi, A. K., Mallawaarachchi, I. & Alvarado, L. A. Analysis of small sample size studies using nonparametric bootstrap test with pooled resampling method. Stat. Med. 36, 2187\u20132205 (2017).","journal-title":"Stat. Med."},{"key":"657_CR38","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/leu.2016.370","volume":"31","author":"IJF Hofman","year":"2017","unstructured":"Hofman, I. J. F. et al. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia 31, 1706\u20131714 (2017).","journal-title":"Leukemia"},{"key":"657_CR39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker, B. A. et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 33, 159\u2013170 (2019).","journal-title":"Leukemia"},{"key":"657_CR40","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.3324\/haematol.2013.090142","volume":"99","author":"M Gambella","year":"2014","unstructured":"Gambella, M. et al. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica 99, e14\u2013e16 (2014).","journal-title":"Haematologica"},{"key":"657_CR41","doi-asserted-by":"crossref","unstructured":"Cohen, Y. C. et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat. Med. 7, 491\u2013503 (2021).","DOI":"10.1038\/s41591-021-01232-w"},{"key":"657_CR42","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","volume":"11","author":"D Alizadeh","year":"2021","unstructured":"Alizadeh, D. et al. IFN\u03b3 is critical for CAR T cell-mediated myeloid activation and induction of endogenous immunity. Cancer Discov. 11, 2248\u20132265 (2021).","journal-title":"Cancer Discov."},{"key":"657_CR43","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2021-154506","volume":"138","author":"DG Coffey","year":"2021","unstructured":"Coffey, D. G. et al. Normalization of the immune microenvironment during lenalidomide maintenance is associated with sustained MRD negativity in patients with multiple myeloma. Blood 138, 329\u2013329 (2021).","journal-title":"Blood"},{"key":"657_CR44","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3324\/haematol.2016.153841","volume":"102","author":"M Bolzoni","year":"2017","unstructured":"Bolzoni, M. et al. IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica 102, 773\u2013784 (2017).","journal-title":"Haematologica"},{"key":"657_CR45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","volume":"35","author":"D Viola","year":"2021","unstructured":"Viola, D. et al. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia 35, 189\u2013200 (2021).","journal-title":"Leukemia"},{"key":"657_CR46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"657_CR47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s42003-021-01938-0","volume":"4","author":"EH Rustad","year":"2021","unstructured":"Rustad, E. H. et al. mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. Commun. Biol. 4, 424 (2021).","journal-title":"Commun. Biol."},{"key":"657_CR48","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"657_CR49","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-018-1603-1","volume":"19","author":"M Stoeckius","year":"2018","unstructured":"Stoeckius, M. et al. Cell hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. Genome Biol. 19, 224 (2018).","journal-title":"Genome Biol."},{"key":"657_CR50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13059-020-1950-6","volume":"21","author":"S Yang","year":"2020","unstructured":"Yang, S. et al. Decontamination of ambient RNA in single-cell RNA-seq with DecontX. Genome Biol. 21, 57 (2020).","journal-title":"Genome Biol."},{"key":"657_CR51","doi-asserted-by":"crossref","unstructured":"Spellerberg, I. F. & Fedor, P. J. A tribute to Claude Shannon (1916\u20132001) and a plea for more rigorous use of species richness, species diversity and the \u2018Shannon\u2013Wiener\u2019Index. Glob. Ecol. Biogeogr. 12, 177\u2013179 (2003).","DOI":"10.1046\/j.1466-822X.2003.00015.x"},{"key":"657_CR52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."},{"key":"657_CR53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"657_CR54","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis.Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/060012v3"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00657-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00657-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00657-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:07:12Z","timestamp":1703117232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00657-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":54,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1038\/s43018-023-00657-1","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"3 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.L. has received research funding from the National Institutes of Health (NIH), NCI, U.S. Food and Drug Administration, MMRF, International Myeloma Foundation, Leukemia and Lymphoma Society, Paula and Rodger Riney Myeloma Foundation, Tow Foundation, Myeloma Solutions Fund, Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Pfizer, Seattle Genetics and Karyopharm; has received honoraria from and\/or served on advisory boards for Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno and Pfizer; and serves on independent data monitoring committees for clinical trials lead by Takeda, Merck, Janssen and Theradex. G.J.M. has received funding from the NIH, NCI, MMRF, Leukemia and Lymphoma Society, Perelman Family Foundation, Amgen, Celgene, Janssen and Takeda; has received honoraria from and\/or served on advisory boards for Adaptive, Amgen, BMS, Celgene and Janssen; and serves on independent data monitoring committees for clinical trials lead by Takeda, Karyopharm and Sanofi. M.S. has received clinical trial research support to the institution from Angiocrine Bioscience, Inc., Omeros Corporation and Amgen, Inc.; has provided consultancy services to Omeros Corporation, Angiocrine Bioscience, Inc. (past) and McKinsey & Company (past); has served on an ad hoc advisory board for Kite \u2013 A Gilead Company (past); and has received honoraria for CME activity from i3Health (past), Medscape, LLC. (past) and CancerNetwork. G.S. has received research funding to the institution from Janssen, Amgen, BMS, and Beyond Spring. DSMB for Arcellx. S.G. receives research funding from Miltenyi Biotec, Takeda Pharmaceutical Co., Celgene Corp., Amgen Inc., Sanofi, Johnson and Johnson, Inc. and Actinium Pharmaceuticals, Inc. and is on advisory boards for Kite Pharmaceuticals, Inc., Celgene Corp., Sanofi, Novartis, Johnson and Johnson, Inc., Amgen Inc., Takeda Pharmaceutical Co., Jazz Pharmaceuticals, Inc. and Actinium Pharmaceuticals, Inc. U.A.S. reports research funding support from Celgene\/BMS and Janssen to the institution and nonfinancial research support; and personal fees from ACCC, MashUp MD, Janssen Biotech, Sanofi, BMS, MJH LifeSciences, Intellisphere, Phillips Gilmore Oncology Communications, i3 Health and RedMedEd outside the submitted work. S.U. has received research funding from Abbvie, Amgen, Array Biopharma, BMS, Celgene, Gilead, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; and has had advisory and\/or consulting roles with Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, K36 Therapeutics, Moderna, Novartis, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda and TeneoBio. A.D. has served as a consultant for Incyte, EUSA Pharma and Loxo and receives research support from Roche and Takeda. B.D. has received honoraria from and served on advisory boards for Janssen and Sanofi. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}